Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 78
Selected: 0
NCT IDTitle
NCT03231501HMPL-813 in Treating Patients With Glioblastoma
NCT03976856Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib
NCT03860532Phase I Clinical Trial in Healthy Male Volunteers
NCT04372394A Study to Assess the Effect of a High Fat Meal on Surufatinib in Healthy Subjects
NCT04557397Fruquintinib CYP3A Inhibitor and Inducer Study
NCT02976116A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer
NCT02601248Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor
NCT02415023A Phase Ib/2 Clinical Study of Fruquintinib Combined With Paclitaxel in the Treatment of Advanced Gastric Cancer
NCT04923945Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients
NCT02196688Study of Fruquintinib in Patients With Metastatic Colorectal Cancer
NCT02589821Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors
NCT04272957A Study of HMPL-306 in Patients With IDH1 and/or IDH2 Mutation of Relapsed/Refractory Myeloid Leukemia/Neoplasms
NCT04716634Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors
NCT04755075Surufatinib Hepatic Impairment Study
NCT02314819A Phase III Trial Evaluating Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients (FRESCO)
NCT02590965A Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer
NCT03223376A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA)
NCT03091192Savolitinib vs. Sunitinib in MET-driven PRCC.
NCT04755088Surufatinib Renal Impairment Study
NCT01955304Food Effect Study of Single Dose of Fruquintinib (HMPL-013) in Healthy Subjects
NCT05277454Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT
NCT04322539A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer
NCT02374645A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC
NCT05318820A Clinical Study to Evaluate the Pharmacokinetics and Bioequivalence of HMPL-523 Tablets Produced by Two Different Manufacturers
NCT02897479A Phase II Study of HMPL-504 in Lung Sarcomatoid Carcinoma and Other Non-small Cell Lung Cancer
NCT06437353Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer
NCT01773018Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors
NCT01882764HMPL-004 Maintenance Treatment in Subjects With Mild to Moderate Ulcerative Colitis
NCT03483259To Explore the Pharmacokinetics and Relative Bioavailability of Sulfatinib Capsules in Two Different Manufacturers
NCT02966821Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma
NCT02631642A Study of HMPL-689 in Healthy Volunteers
NCT01805791A Phase III Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis
NCT02614495Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma
NCT05173142A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid Tumors
NCT00659802Phase II Study of HMPL-004 in Patients With Ulcerative Colitis
NCT05015621A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma
NCT03684967Study of Fruquintinib (HMPL-013) in High Risk Patients With Advanced NSCLC
NCT04510649Surufatinib DDI With a PPI and a CYP3A Inducer
NCT04645940Fruquintinib Food Effect and Proton Pump Inhibitor Study
NCT01975077A Phase Ib Study of Fruquintinib in 3rd Line mCRC
NCT01645215Phase I Study of Fruquintinib(HMPL-013) in Patients With Advanced Solid Tumors
NCT04169672Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors
NCT00655733Phase II Study of HMPL-004 in Subjects With Crohn's Disease
NCT03251378A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers
NCT04849351Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma
NCT03977090Geptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer
NCT03128164A Study of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or no Standard of Care Existed
NCT02267967Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors
NCT04290325HMPL-453 in Advanced Malignant Mesothelioma
NCT04923932Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients